Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

The Carlyle Group Inc. - Common Stock (NQ:CG)

47.07 +0.97 (+2.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about The Carlyle Group Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Is the Market Bullish or Bearish on Carlyle Group?
Via Benzinga
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
From bluebird bio, Inc.
Via Business Wire
Carlyle Group Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Via Benzinga
Is Carlyle Group Gaining or Losing Market Support?
Via Benzinga
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
From bluebird bio, Inc.
Via Business Wire
Price Over Earnings Overview: Carlyle Group
Via Benzinga
Carlyle CEO Harvey Schwartz Says 'Stay Buckled' Amid Market Turmoil – 'It's Just A Question Of Whether The Airbags Come Out
Via Benzinga
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
From bluebird bio, Inc.
Via Business Wire
Acentra Health Supports Utah in Securing CMS Certification for Medicaid Enterprise System Modernization
Milestone highlights Acentra Health’s pivotal role in supporting state Medicaid modernization and eligibility platform transformation 
From Acentra Health
Via GlobeNewswire
Earnings Scheduled For May 8, 2025
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
What's Driving the Market Sentiment Around Carlyle Group?
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET. 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Analyst Verdict: Carlyle Group In The Eyes Of 6 Experts
Via Benzinga
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
From bluebird bio, Inc.
Via Business Wire
Acentra Health Awarded $27.5 Million Contract from California Medicaid to Continue Providing Preadmission Screening and Resident Review (PASRR) Services
Award follows new contracts in Kansas and Washington and expands the company’s PASRR services for long-term care assessments to eight states 
From Acentra Health
Via GlobeNewswire
Bill Miller's Q4 Additions Struggle Amid Market Uncertainty, What Else Is Dragging Them Down?
Bill Miller IV‘s investment firm has seen significant losses in its fourth-quarter portfolio additions as market uncertainties persist. 
Via Benzinga
Socially Determined and Acentra Health Partner to Advance Whole Person, Whole Population Healthcare through Enhanced Analytics
From Acentra Health
Via GlobeNewswire
Is Carlyle Group Gaining or Losing Market Support?
Via Benzinga
SoftBank Buys Silicon Valley Firm As It Goes All-In On AI
This is the third big AI move the bank has made this year. 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Masayoshi Son's SoftBank Buys Oracle-Backed Ampere For $6.5 Billion To Boost US AI Push
SoftBank has acquired Oracle-backed Ampere for $6.5 billion to strengthen its AI infrastructure strategy in the U.S., marking a major step in its broader push into Arm-based computing and large-scale... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Oppenheimer Analysts Slash Estimates For Goldman Sachs, Jefferies Amid Subdued M&A Activity
Analysts expect rebound in M&A and financing activity, but uncertainties may pause it. Estimates slashed for GS and JEF, CG downgraded to Perform. 
Via Benzinga
Tariffs Tangle Markets, Businesses, Investors
When uncertainty spikes, our ability to look out into the future shrinks. 
Via The Motley Fool
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
bluebird bio agrees to be acquired by Carlyle Group and SK Capital, offering stockholders up to $9.84 per share in a strategic buyout. 
Via Benzinga
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
From bluebird bio, Inc.
Via Business Wire
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
U.S. 
Via Benzinga
Carlyle Group Stock Slips After Q4 Profit Miss: Retail Remains Neutral
The company’s fee-earning assets under management (AUM) fell by 1% to $304 billion compared with last year. 
Via Stocktwits
Acentra Health Welcomes Distinguished Public Sector Health Leaders Calder Lynch and Jami Snyder to its Healthcare Advisory Board; Appoints Julie Boughn as New Chair
Industry experts join board of seasoned advisors offering strategic counsel on healthcare trends and policy for the company and its portfolio of state, federal, and commercial clients 
From Acentra Health
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.